Recombinant Human Nogo

Background

Noggin (NOG) is a secreted glycoprotein that plays a critical role in regulating embryonic development and tissue homeostasis. It functions as an antagonist of bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta (TGF-β) superfamily. By binding directly to BMPs such as BMP-2, BMP-4, and BMP-7, Noggin inhibits their ability to interact with receptors on the cell surface, thereby preventing the activation of downstream signaling pathways. This modulation is essential for proper skeletal development, including joint formation and bone growth, as well as the differentiation of neural and mesenchymal tissues. Noggin is expressed in various embryonic structures, including the notochord and somites, and its spatial and temporal expression is tightly regulated to ensure normal development. Mutations or dysregulation of NOG can result in skeletal disorders such as symphalangism and multiple synostoses syndrome. Noggin has also been implicated in processes like wound healing, cancer, and fibrosis, where BMP signaling plays a role. As a therapeutic target, Noggin's ability to modulate BMP activity makes it a potential candidate for treating conditions like osteoporosis and fibrodysplasia ossificans progressiva (FOP). Its role in tissue engineering and regenerative medicine is also being explored.